The National Institute for Health and Care Excellence (NICE) has published Final Guidance on a new medicine for the treatment of the most common inherited heart condition in England and Wales.
Mavacamten—branded by US pharma major Bristol Myers Squibb (NYSE: BMY) as Camzyos—will now be available on the National Health Service (NHS) as a treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The final guidance recommends this product in eligible patients as an add-on to individually optimised standard care, including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze